Show simple item record

dc.contributor.authorQuiñonero Muñoz, Francisco José 
dc.contributor.authorMesas Hernández, Cristina 
dc.contributor.authorMuñoz Gámez, José Antonio
dc.contributor.authorJiménez Luna, Cristina 
dc.contributor.authorPerazzoli, Gloria
dc.contributor.authorPrados Salazar, José Carlos 
dc.contributor.authorMelguizo Alonso, Consolación 
dc.contributor.authorOrtiz Quesada, Raúl 
dc.date.accessioned2022-10-28T11:54:25Z
dc.date.available2022-10-28T11:54:25Z
dc.date.issued2022-09-13
dc.identifier.citationYlenia Jabalera... [et al.]. Antimicrobial defenses of table eggs: Importance of antibacterial proteins in egg white as a function of hen age in an extended production cycle, Food Microbiology, Volume 107, 2022, 104068, ISSN 0740-0020, [https://doi.org/10.1016/j.fm.2022.104068]es_ES
dc.identifier.urihttps://hdl.handle.net/10481/77618
dc.description.abstractPancreatic cancer (PC) is one of the tumors with the lowest survival rates due to the poor efficacy of the treatments currently used. Gemcitabine (GMZ), one of the chemotherapeutic agents employed when the tumor is unresectable, frequently fails due to the development of drug resistance. PARP1 is a relevant protein in this phenomenon and appears to be related to cancer progression in several types of tumors, including PC. To determine the relevance of PARP1 in the development and treatment of PC, we used the Panc02 cell line to generate modified PC cells with stably inhibited PARP1 expression (Panc02-L) and used GMZ, Olaparib (OLA) and GMZ+OLA as therapeutic strategies. Viability, radiosensitization, angiogenesis, migration, colony formation, TUNEL, cell cycle, multicellular tumorsphere induction and in vivo assays were performed to test the influence of PARP1 inhibition on resistance phenomena and tumor progression. We demonstrated that stable inhibition or pharmacological blockade of PARP1 using OLA-sensitized Panc02 cells against GMZ significantly decreased their IC50, reducing colony formation capacity, cell migration and vessel formation (angiogenesis) in vitro. Furthermore, in vivo analyses revealed that Panc02-L-derived (PARP1-inhibited) tumors showed less growth and lethality, and that GMZ+OLA treatment significantly reduced tumor growth. In conclusion, PARP1 inhibition, both alone and in combination with GMZ, enhances the effectiveness of this chemotherapeutic agent and represents a promising strategy for the treatment of PC.es_ES
dc.description.sponsorshipGranada University and ibs. GRANADA INB-009es_ES
dc.description.sponsorshipInstituto de Salud Carlos III European Commission DTS17/00081es_ES
dc.description.sponsorshipJunta de Andalucia (FEDER) (Spain) CTS-107 A-CTS-666UGR20 B-CTS-122-UGR20es_ES
dc.description.sponsorshipMinisterio de Educaci 'on, Ciencia y Deporte y Competitividad (Spain)es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPARP1es_ES
dc.subjectPancreatic canceres_ES
dc.subjectOlaparibes_ES
dc.subjectGemcitabinees_ES
dc.subjectDrug resistancees_ES
dc.titlePARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabinees_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1016/j.fm.2022.104068
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional